Given that FADS1 activity is reduced in MASLD patients [13,14] and FADS1 deficiency worsens hepatic steatosis and cholesterol metabolism [15,18], we hypothesize that overexpression of Fads1 in hepatocytes improves MASLD and metabolic phenotypes. Here, FADS1 is linked to fatty liver disease.